Ongoing trials of immune checkpoint blockade in multiple myeloma
Data compiled from ClinicalTrials.gov (https://clinicaltrials.gov) 7/2016.
| Type | Therapy | Primary Outcome | Inclusion | Clinicaltrials.gov Identifier |
|---|---|---|---|---|
| Phase 1 | Nivolumab, nivolumab + ipilumab, nivolumab + lirilumab | Toxicity | Relapsed/refractory lymphoma and MM | NCT01592370 |
| Phase 1 | Atezolizumab | Toxicity | Solid tumors, refractory lymphoma and MM | NCT01375842 |
| Phase 1/1b | Ipilimumab or Nivolumab | Toxicity and dose-finding | Hematologic malignancies, including MM, after allo-SCT | NCT01822509 |
| Phase 1/2 | Pembrolizumab + pomalidomide + dexamethasone | Toxicity | Relapsed/refractory MM | NCT02289222 |
| Phase 1/2 | Pidilizumab + lenalidomide | Pidilizumab MTD ORR | Relapsed/refractory MM | NCT02077959 |
| Phase 2 | Pembrolizumab | Clinical response | MM after auto-SCT | NCT02331368 |
| Phase 2 | Pidilizumab+ DC vaccine | Immunologic response | MM after auto-SCT | NCT01067287 |
| Phase 2 | Pembrolizumab | ORR | Residual MM | NCT02636010 |
| Phase 3 | Lenalidomide + dexamethasone +/− pembrolizumab | PFS | Newly diagnosed MM | NCT02579863 |
| Phase 3 | Pomalidomide + dexamethasone +/− pembrolizumab | PFS and OS | Relapsed/refractory MM | NCT02576977 |
MM, multiple myeloma; allo-SCT, allogeneic stem cell transplantation; CR, complete response; auto-SCT, autologous stem cell transplantation; MTD, maximal tolerated dose; ORR, overall response rate; PFS, progression free survival; overall survival.